The vials move along a transporter at the production facilities of Novo Nordisk A/S in Hillerod, Denmark, on Monday, June 12, 2023. The success of the Bestsellers of Novo Ozempic and Wogovy, drugs that help people lose a significant amount stood Companies developing products that will be intense competition.
Bloomberg | Bloomberg | Getty images
Denmark’s economic growth is expected, that economists are due to an “exceptional increase” in pharmaceutical exports, wake up this year, but the imminent threat of US tariffs in the pharmaceutical industry will not reach much a financing factor, according to the factor of the conclusion, according to the internal factor.
The IMF, on Tuesday, said on Tuesday in its latest report on the Nordic country that expects Denmark, whose economy grew 3.7% in 2024, see its moderate production to 2.9% this year and 1.8% in 2026. The decreases must be taken, in the middle of -to -take, amid to a amid -ups, amid to asha, amid -Up pharmaceutical products.
The Neverpertess fund pointed out that Dhark will be protected from possible US tariffs on pharmaceutical imports, since most Danish pharmaceutical products do not occur in the country or cross their borders.
Danish medication manufacturers have become increasingly dependent on a “merchant and processing” system in which most of the value of medications is attributable to intellectual property integrated into them, with medicines companies that hire manufacturers.
“USA. It is a key trade partner; however, exports produced in Denmark that pass through customs represent only 3 percent of total exports, which limits the direct impact of the United States tariff -Eagle -Eagle -Eagle -Eagle -Eagle -Eagle -Eagle -Eagle -Eagle -eagleed.
Beyond 2026, said the fund, the medium -term growth is projected by around 1.5%, “reflecting a pharmaceutical sector in maturation and a population of working age in decline.”
The past fall, IMF economists commented that the growth of Denmark had been driven by an “exceptional increase” in its pharmaceutical industry, while the rest of the economy had remained “relatively subject.”
The background highlighted the mass increase of the Danish pharmaceutical giant of Novo Nordisk in the foreign demand of its diabetes and the medications for weight loss, Wogovy and Ozempic, as a growth driver, noting that the company’s sales as a part of Dhar de Traded Traded 2023.
Imminent threat raised by Trump
A largest wind for the broader pharmaceutical industry of the European is the threat of the president of the United States, Donald Trump, to impose tariffs on drug imports.
The pharmaceutical products were exempt from the initial regime of “reciprocal” tariffs of Trump announced in April, but the president has set his gaze in the global industry, threatening to place separate taxes on the prices of the USA. UU. And demanding data data data.
When indicating his intention on the matter, Trump signed an executive order on Monday that ordered drug manufacturers to lower the prices of their drugs to align with the lowest significant prices paid abroad.
The president did not refer to specific nations, but said he would go to other developed countries because there are some countries that need additional help, and that is fine. “
“Basically, what we are doing is matching,” Trump said a press event on Monday. “We are going to pay the lowest price in the world. We will obtain whoever is paying the lowest price, that is the price we are going to get.”
White House officials did not deactivate which medications the order will apply, but they said it will affect the commercial market, as well as Medicare and Medicaid.
In 2022, US prices in all medications (brands and generic) were almost three times higher than prices in 33 countries to compare OECD, according to the data published in 2024 by the Department of Health and Human Services of the United States.
The president of the United States, Donald Trump, gestures on the day he signs an executive order on the duration of prescription drugs, a press conference in the Roosevelt room at the White House in Washington, DC, USA. UU., May 12, 2025. Reuters/Nathan Howard
Nathan Howard | Reuters
The threat of tariffs on pharmaceutical imports has been described as a “Damocles sword” that hangs on the pharmaceutical industry of Europe, with CEO warning that they could be an exodus of the main continental actors to the United States in an attempt to avoid taxes.
The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represses the main European pharmaceutical companies, including Novo Nordisk, Bayer” Astrazeneca” GSK” Roche and Healthy – Warned the president of the European Commission, Ursula von der Leyen, in April that “unless European deliver a rapid and radical policy change, then it is increasingly likely that research, development and pharmaceutical manufacture is directed” towards the United States “
He said that a survey of its members showed that around 100 billion euros ($ 112 billion) in capital expenses and research and development investments were at risk as a result.
“The Us Now Leads Europe on Every Investor Metric From Availability of Capital, Intellectual Property, Speed of Approval To Rewards for Innovation. In Addition to The Uncertainty Created by The Treat of Tacts, There Is Little Tcentive To The Tcentive To The Tcentive To The Tentive To The Tentive To The Tcent To The Tcentive to the tcentive to the tcentive to the tcent to the tcentive to the tcentive to the tcent to the tcentive to the centivo to the centivo to the centivo to the tentle centive to the small centivo to the centivo to the tentive to the tentine tentine to the centiva to the temptive to the tentle that the Tentle said.
– Annika Kim Constantino and Karen Gilchrist of CNBC contributed to this story
